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Background: Several studies suggest an increase of oxidative stress and a reduction of endothelial function in
obstructive sleep apnoea syndrome (OSAS). We assessed the association between OSAS, endothelial dysfunction
and oxidative stress. Further aim was to evaluate the effect of nasal continuous positive airway pressure (nCPAP)
on oxidative stress and arterial dysfunction.
Methods: We studied 138 consecutive patients with heavy snoring and possible OSAS. Patients underwent
unattended overnight home polysomnography. Ten patients with severe OSAS were revaluated after 6 months of
nCPAP therapy. To assess oxidative stress in vivo, we measured urinary 8-iso-PGF2α and serum levels of soluble
NOX2-derived peptide (sNOX2-dp). Serum levels of nitrite/nitrate (NOx) were also determined. Flow-mediated
brachial artery dilation (FMD) was measured to asses endothelial function.
Results: Patients with severe OSAS had higher urinary 8-iso-PGF2α (p<0.001) and serum NOX2 and lower NOx.
A negative association was observed between FMD and OSA severity. Apnea/hypopnea index was significantly
correlated with the indices of central obesity and with urinary 8-isoprostanes (r=0.298, p<0.001). The metabolic
syndrome (t=-4.63, p<0.001) and urinary 8-isoprostanes (t=-2.02, p<0.05) were the only independent predictors of
FMD. After 6-months nCPAP treatment, a significant decrease of serum NOX2, (p<0.005) and urinary 8-iso-PGF2α
(p<0.01) was observed, while serum NOx showed only a minor increase. A statistically significant increase of FMD
was observed (from 3.6% to 7.0%).
Conclusions: The results of our study indicate that patients with OSAS and cardiometabolic comorbidities have
increased oxidative stress and arterial dysfunction that are partially reversed by nCPAP treatment.Background
Obstructive sleep apnoea syndrome (OSAS) is a com-
mon nocturnal disorder characterized by the presence of
repetitive apnoea and hypopnoea during sleep, daytime
sleepiness and cardiopulmonary dysfunction. Patients
with OSAS experience recurrent episodes of cessation
of breathing which expose the cardiovascular system* Correspondence: francesco.angelico@uniroma1.it
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reproduction in any medium, provided the orto cycles of hypoxia, exaggerated negative intrathoracic
pressure and arousals [1].
The majority of OSAS patients show the cluster of
metabolic and non-metabolic cardiovascular risk factors
of the metabolic syndrome and it has also suggested that
OSA may be a manifestation of metabolic syndrome
(MS) [2-4].
Several studies have provided evidence supporting an
increase of oxidative stress in OSAS [5-10]. Oxidative
stress is characterized by an imbalance between oxidant
and antioxidant mechanisms, in which many different
enzymatic and non-enzymatic antioxidants take place.
Recently, it has been postulated that intermittent hypoxial Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inflammation in response to hypoxia may be clinically
relevant. [11]. Previous studies have also demonstrated
that total nitrate and nitrite (NOx) production is lower
in OSAS patients than in controls [12,13]. Both oxidative
stress and inflammation are major components in the
initiation and development of endothelial dysfunction,
which is widely accepted as an early marker of athero-
sclerosis. Flow-mediated, brachial artery vasodilation
(FMD) is a well established marker of endothelial func-
tion, as the result of endothelial release of NO [14-16].
Endothelial function, which is the result of a reduction
in NO bioavailability, is markedly reduced in patients
with moderate/severe OSAS [17-23]. Chronic low-grade
inflammation, oxidative stress, metabolic abnormalities
and endothelial dysfunction in OSAS could accelerate
atherogenesis. However, so far, the biological mechan-
isms which may explain the association of OSA with
endothelial dysfunction are still under debate.
Nasal continuous positive airway pressure (nCPAP) is
first-line therapy for OSAS to reduce daytime sleepiness
and improve cardiovascular and metabolic outcomes
[24]. Previous studies have demonstrated a beneficial
effect of nCPAP on several markers of oxidative stress in
patients with OSAS [25-29]. An improvement of arterial
dysfunction after nCPAP therapy has been also demon-
strated [12,30-33].
Aim of our study was to assess the association be-
tween OSAS, endothelial dysfunction and oxidative
stress in a sample of patients with different severity of
OSAS. Further aim was to evaluate the effect of nCPAP
on FMD and the levels of markers of systemic oxidative




The study group consisted of 138 consecutive patients
who were referred to our metabolic outpatients clinic
because of suspected metabolic disorders with heavy
snoring and possible OSAS. All patients had a complete
clinical and biochemical work up, including polysomno-
graphy (PSG), as part of routine clinical examination.
Written consent was obtained from all subjects before
the study and the study conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki. The research
protocol was approved by the University Department of
Experimental Medicine and Pathology scientific board in
2004. According to the Hospital Ethical Committee
guidelines, ethical approval was not required since the
study was observational and did not include the use of
new drugs and/or new experimental treatments. To be
eligible for the study, patients had to fulfil the following
criteria: no history and clinical signs of heart failure,autoimmune disease, acute inflammatory disease, or any
severe disease shortening life expectancy, such as diag-
nosed cancer, chronic liver disease, severe renal disease.
Arterial blood pressure was measured on the right
arm with the subjects in a sitting position and after a
5-min rest, using a mercury sphygmomanometer: the
average of two measurements, 1 min apart, was con-
sidered. Waist circumference, height and weight were
recorded with subjects wearing light clothing, without
shoes and body mass index (BMI) was calculated as
weight (Kg) divided by height (m2). MS was diagnosed
following the International Diabetes Federation criteria
[34]. Diabetes was diagnosed according to the WHO cri-
teria. Subjects taking insulin or oral antidiabetic drugs
were considered to have diabetes.
Flow-mediated vasodilatation
Ultrasound assessment of endothelial dependent and
independent FMD of brachial artery was investigated
according to the recently reported guideline [16]. Briefly,
the study was performed in a temperature-controlled
room (22°C) with the subjects in a resting, supine state
between 8 a.m. and 10 a.m. after at least a 8-hour fasting;
brachial artery diameter was imaged using a 7.5-Mhz
linear array transducer ultrasound system (Siemens)
equipped with electronic callipers, vascular software for
two-dimensional imaging, colour and spectral Doppler,
and internal electrocardiogram; the brachial artery was
imaged at a location 3–7 cm above the antecubital
crease; to create a flow stimulus in the brachial artery, a
sphygmomanometric cuff was placed on the forearm; the
cuff was inflated at least 50 mmHg above systolic pres-
sure to occlude artery inflow for 5 min; all vasodilatation
measurements were made at the end of diastole; FMD
was expressed as a change in post-stimulus diameter
evaluated as a percentage of the baseline diameter.
Blood sampling protocol
Fasting venous blood samples were taken in the supine
position on the morning after performing polysomno-
graphy and stored at −80°C until assay. A final morning
fasting blood sample was obtained after using CPAP
treatment for a period of six months.
Subjects underwent routine biochemical evaluation in-
cluding fasting total and HDL-cholesterol, triglycerides,
glucose and insulin. Serum total cholesterol, HDL-
cholesterol and triglycerides were measured by an Olym-
pus AN 560 apparatus using an enzymatic colorimetric
method. LDL-cholesterol levels were calculated accord-
ing to the Friedwald formula. Plasma insulin levels were
assayed by commercially available radioimmunoassay.
The homeostasis model assessment (HOMA-IR) was
used to estimate insulin resistance using the formula:
glucose (mmol/L) x [insulin (mU/L)/22.
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to determine nitric oxide metabolites nitrite and nitrate
(NOx) in the serum. Intra-assay and interassay coeffi-
cients of variation were 2.9% and 1.7% respectively.
Serum levels of soluble NOX2-derived peptide
(sNOX2-dp) were detected by ELISA method as previ-
ously described [35]; intra-assay and inter-assay coeffi-
cients of variation were 5.2% and 6%, respectively.
Values are expressed as pg/ml.
Urinary 8-iso-prostaglandin F2α (8-iso-PGF2α) was
measured by a previously described and validated enzyme
immunoassay method [36]. Intra-assay and inter-assay
coefficients of variation were 2.1% and 4.5%, respectively.
Polysomnography (nocturnal recording)
Patients underwent unattended overnight home PSG
using a overnight home sleep recording (Embletta, PDS;
Medcare, Reykjavik, Iceland). The device recorded nasal
and oral airflow, chest and abdominal movements, and
pulse oximetry. The sleep recordings were downloaded
to a computer and scored by a principal investigator.
A minimum of 5 hours of recording was accepted to be
adequate for scoring. The presence and severity of apnea
was assessed based on the number of apnoea/hypopnoea
episodes per hour of sleep (apnoea/hypopnoea index
AHI). Apnea was defined as continuous cessation of air-
flow for more than 10-s and hypopnoea was defined as
reduction of airflow for more than-10 s with oxygen de-
saturation of ≥4% and arousal. OSAS was defined as an
AHI of ≥5. Patients were categorized into four sub-
groups according to OSA severity, as follows; normal
AHI <5 events/h; mild OSA, AHI <5 to <15 events/h;
moderate OSA, AHI <15 to <30 events/h; severe OSA,
AHI ≥30 events/h.
Patients had overnight home pulse oximetry monitor-
ing with a transcutaneous fingertip sensor connected via
cable to an OhmedaBiox 3700 pulse oximeter (Louisville,
CO). The mean haemoglobin oxygen saturation level
(SaO2) in total sleep time was also calculated.
Patients with severe OSAS underwent a full-night
nCPAP titration study at home using an automated pres-
sure setting device. The first consecutive 10 patients
with severe OSAS who adhered to nCPAP treatment
over a period of six months were revaluated.
Adherence to nCPAP was defined as nCPAP use for at
least 4 hours per night and 5 days per week.
Statistical analysis
Statistical analysis was performed by using the SPSS stat-
istical software version 11.0 for Windows (SPSS,Inc.,Chi-
cago.Illinois). All variables were tested for normal
distribution prior to analyses. Data are expressed as
the mean ± SD for continuous variables. The correlation
between variables was analysed with the Pearson and theSpearman tests. Student’s t-test for unpaired data was
used for the comparison of mean values. Group compar-
isons were performed by use of analysis of variance and
test for linear trend in One-way ANOVA. Proportions
and categorical variables were tested by the χ2–test
and by the 2-tailed Fisher’s exact method when appro-
priate. Multiple linear regression analysis was performed
to determine the independent predictors of FMD. All
P-values are two-tailed; a P-value of less than 0.05 was
considered statistically significant.
Results
Out of the 138 patients who performed overnight poly-
somnography, 47 had a primary snoring and 91 had
a positive polysomnography for OSA: 61 had mild/
moderate and 30 severe OSA.
Clinical and metabolic characteristics of patients with
OSA by severity and control snorers are reported in
Table 1. A strong positive association was observed be-
tween OSA severity and the indices of central obesity, i.e.
body mass index (p=<0.01) and waist and hip circumfer-
ences (p<0.001). In addition, a positive association was
observed with serum insulin and HOMA-IR level and
with urinary 8-iso-PGF2α concentration. As compared to
non-OSAS, patients with severe OSAS had statistically
significant higher urinary 8-iso-PGF2α and higher serum
sNOX2-dp and lower NOx, although not at a statistically
significant extent. Furthermore, a statistically significant
negative association was observed between FMD and
OSA severity.
Table 2 shows the prevalence of MS and its compo-
nents in patients with different severity of OSAS. A sta-
tistically significant increase in the prevalence of central
obesity was observed from snorers to subjects with se-
vere OSAS (p=0.012), although a positive trend was also
observed for the other components of MS. Fifty-six per-
cent of patients with OSAS had MS, and 62.6%, 30.0%
and 67.1% had hypertension, hyperlipidemia and hyper-
glycemia and/or type 2 diabetes, respectively.
Table 3 shows bivariate correlations between AHI and
some clinical and metabolic characteristics. AHI was sig-
nificantly correlated with the indices of central obesity
and with urinary 8-isoprostanes (r=0.298, p<0.001). In
turn, urinary 8-iso-PGF2α were positively correlated
with sNOX2-dp (r=0.250, p<0.01) and negatively corre-
lated with NOx (r=0.360, p<0.001). A negative correl-
ation was also observed between FMD and waist
circumference (r=-0.199; p<0.05), serum insulin and
triglyceride levels (r=-0.241; p=0.01 and r=-0.238;
p<0.01 respectively) and the metabolic score (r=-0.335;
p<0.001).
In a stepwise multiple regression analysis including
age, gender, waist circumference, AHI, Sa02, HOMA-IR,
total cholesterol, systolic blood pressure, diabetes, urinary
Table 1 Clinical and metabolic characteristics of patients with OSA by severity and control snorers
O S A
snorers mild/moderate severe
AHI<5 n=47 AHI 5 – 29 n=61 AHI≥30 n=30 P
Age 51.3±11.7 53.2±11.7 56.6±9.8 NS
Males (%) 66.0 70.5 83.3 NS
AHI (events/h) 1.2±1.4 14.6±8.0 42.8±14.2 <0.001
Average SaO² 95,0±1,4 93,6±2,2 92,6±2,5 <0,01
Body Mass Index (kg/m2) 29,3±3,9 30,5±4,5 32,8±5,1 <0,01
Waist circumference (cm) 102,5±11,1 105,8±12,1 113,6±12,1 <0,001
Hip circumference (cm) 106,5±8,5 109,9±9,1 116,9±11,7 <0,001
Blood glucose (mg/dl) 103.1±24.5 107.5±41.5 107.1±28.1 0.428
Insulin (μU/mL) 14.0±6.7 19.2±19.3 24.4±22.4 <0.05
HOMA-IR 3.6±1.9 5.8±6.8 8.4±11.1 <0.01
Total cholesterol (mg/dl) 210.4±41.4 201.4±38.7 207.9±39.9 NS
LDL-cholesterol (mg/dl) 137.7±35.2 128.0±33.7 128.8±33.3 NS
HDL-cholesterol (mg/dl) 46.8±11.5 46.0±11.5 45.8±9.9 NS
Triglycerides (mg/dl) 131.1±65.8 136.1±80.7 167.5±134.0 NS
Urinary 8-iso-PGF2α (pg/mg creatinine) 284.0±77,3 289.5±77,0 337.6±74.5 <0.001
sNOX2-dp (pg/ml) 26.2±8,2 26.3±7.5 28,8±8.0 NS
Serum NOx (uM/ml) 27.1±14.6 27.0±12,5 23,6±16.0 NS
FMD% 6.2±3.2 7.2±4.6 4.9±2.7 <0.05
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-0.40, t=-4.63, p<0.001 ) and urinary 8-iso-PGF2α (β=
-0.17, t=-2.02, p<0.05) were the only independent predic-
tors of FMD (R2=0.18).
Changes before and after CPAP treatment observed in
the first consecutive 10 patients with severe OSAS who
were compliant to CPAP treatment over a period of six
months. are shown in Table 4. During treatment, mean
HAI of the patients was significantly decreased from 43.4
±12.6 at baseline to 7.0±5.0 (p<0.001), while mean Sa02
increased from 91.8±3.7 to 97.0±1.0 (p=0.001). A statisti-
cally significant decrease of mean serum sNOX2-dp
(p<0.005) and of urinary 8-iso-PGF2α ( p<0.01) was









All Metabolic syndrome* 46,8
Metabolic syndrome* with diabetes 8,5
SCORE Metabolic Syndrome 2.1±1.2
*according to IFD criteria (Ref. [34]).statistically non significant increase. A statistically significant
increase of FMD was also observed (from 3.6% to 7.0%).
During the six months treatment, no significant change in
body weight or cardiovascular risk factors was observed.
Discussion
In our study, patients with severe OSA syndrome presented
increased systemic oxidative stress. To assess oxidative
stress in vivo, we measured urinary 8-isoprostanes, which
are reliable markers of lipoperoxidation and, for the first
time, sNOX2-dp, a marker of NOX2 activation by blood
cells, which is a ROS generating enzyme implicated in ar-
terial function via oxidative-stress mediated NO inactiva-
tion [3,37,38].h different severity of OSAS
mild/moderate severe














Average SaO2 -0.386 <0,01
Body Mass Index (kg/m2) 0.271 <0,01
Waist circumference (cm) 0.294 <0.001
Hip circumference (cm) 0.295 <0.001
Blood glucose (mg/dl) 0.015 NS
Insulin (μU/mL) 0.249 <0.01
HOMA-IR 0.284 <0.01
Total cholesterol (mg/dl) -0.034 NS
LDL-cholesterol (mg/dl) -0.102 NS
HDL-cholesterol (mg/dl) -0.055 NS
Triglycerides (mg/dl) 0.056 NS
Urinary 8-iso-PGF2α (pg/mg creatinine) 0.298 <0.001
sNOX2-dp (pg/ml) 0.013 NS
Serum NOx (uM/ml) -0.135 NS
FMD% -0.166 NS
Metabolic score 0.159 NS
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cantly higher 8-iso-PGF2α urinary levels than healthy
controls and that the severity of OSA was significantly
correlated with the oxidative stress. In addition, severe
OSAS had a tendency towards higher serum sNOX2-dp
and lower serum nitrate and nitrite (NOx), which are
stable NO derivatives, reflecting overall NO production.
In keeping with the above results, we found a statistically
significant decreased FMD in patients with severe OSAS.
At multivariate analysis, MS and urinary 8-iso-PGF2α
were independent predictors of FMD suggesting that in
patients with OSA oxidative stress promotes arterial dys-
function likely via NO biosynthesis and/or inactivation.
Moreover, as already reported, we further confirmed
the strong association between MS and endothelial dys-
function [4].Table 4 Changes before and after nCPAP treatment in 10
patients with severe OSAS
Baseline After C-PAP P
Body Mass Index (kg/m2) 35.3±5.4 36.0±6.0 NS
AHI (events/h) 43.4±12.6 7±5 0.000
ODI (events/h) 35.8±23.5 2.8±1.6 0.002




sNOX2-dp (pg/ml) 38.2±7.4 29±3.2 0.003
Serum NOx (uM/ml) 23.9±3.23 27.3±5 NS
FMD (%) 3.64±4.2 7.0±4.7 0.015However, earlier studies of oxidative stress in OSAS
provided conflicting results. Yamauchi et al. [39] found
increased urinary 8-hydroxy-20-deoxyguanosine (8-OhdG)
excretion in the severe OSA patients, Carpagnano et al.
[10] observed elevated 8-isoprostane levels in the exhaled
breath condensate in OSA patients and Dyugovskaya
et al. [40] detected an increase in the production of
ROS in OSA. Several other studies reported abnormal
lipid peroxidation in OSAS [7,8] or reduced total antioxi-
dant status [9]. Conversely, Wali et al. [41] found no dif-
ferences in susceptibility of LDL to oxidative stress
and Svatikova et al. [42] reported that patients with mod-
erate – severe OSA did not have evidence for greater
oxidative stress and lipid peroxidation than healthy nor-
mal subjects. Negative results were also obtained in a
recent study by Lee et al. [6] where no significant differ-
ence in either oxidative stress or antioxidant status mar-
kers was observed among normal patients and those with
moderate and severe OSA; in this study, oxidative stress
was related to central obesity rather than intermittent
hypoxia and waist-to- hip ratio was a significant inde-
pendent variable of oxidized-LDL, glutathione peroxidase,
total antioxidant status and superoxide-dismutase.
In our study patients with OSA had reduced FMD, a
widely used non invasive method to measure endothelial
dysfunction. This is in agreement with the results
reported by Oflaz et al. [19] and Grebe et al [43] who
found a significant reduction of FMD in patients with
OSA without other co-morbidities compared to healthy
subjects; moreover, in the last study, the administration
of i.v. vitamin C improved endothelial function in OSAS
patients, leading to an increase of FMD to a level compar-
able to that observed in the control group. Similar find-
ings were obtained by Büchner et al. [26] who found that
endothelial function in OSAS patients improved either
after infusion of vitamin C or after nCPAP treatment.
Conversely, Kato et al. [44] found no differences in
FMD between OSA patients free of other diseases and
healthy controls, although endothelium-dependent vaso-
dilation tested by use of forearm blood flow responses to
intra-arterial infusion of acetylcholine showed a blunted
vasodilation in OSA patients.
In studies conducted by Chung et al. [45], oxygen desat-
uration index was the only significant determinant of FMD.
Finally, in keeping with the above studies, Ip et al. [46]
demonstrated that subjects with OSA had lower FMD
compared with subjects without OSA and that major deter-
minants of FMD in OSA patients were AHI and age.
The above data raise the question whether OSA itself
results in oxidative stress and arterial dysfunction or
it is simply a consequence of metabolic comorbidities
frequently associated to OSAS. In fact, in a previous
paper, we provided evidence that MS patients have lower
FMD and NOx serum levels and increased urinary 8-
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to controls [47]. Thus, we acknowledge that MS and sev-
eral potential confounders may influence oxidative stress
in OSAS.
In our study, the first 10 patients with severe OSAS
who adhered to nCPAP therapy were revaluated. Long-
term compliance to nCPAP therapy was found to be ef-
fective in reducing the levels of systemic oxidative stress.
In fact, nCPAP therapy normalized urinary 8-iso-PGF2α
and serum sNOX2-dp values even though there was no
significant change in body weight or cardiovascular risk
factors during the six months treatment.
Our findings are in keeping with the results of several
uncontrolled studies showing that short and long term
nCPAP reduces oxidative stress in OSAS patients [7-10,
25,27,28].
Conversely, in a study of 41 moderate-severe OSAS with-
out other diseases, 4 h treatment with nCPAP did not affect
plasma levels of isoprostanes and other markers of oxida-
tive stress [41]. Moreover, one night nCPAP therapy did
not significantly change the susceptibility of LDL to peroxi-
dation and the levels of the antioxidant enzymes [42].
In our study, FMD showed a statistically significant
increase after nCPAP over a six months period. This is in
keeping with recently reported data [23,31,32,47]. More-
over, FMD significantly improved 1 week and 4 weeks after
nCPAP in 10 male OSA patients concomitantly with an in-
crease of plasma NOx concentrations, and a correlation be-
tween the two was observed [12]. Finally, FMD and
endothelial nitric oxide production increased whereas ex-
pression of NFkB and nitrotyrosine decreased in patients
who adhered to CPAP >4 hours daily [48].
In addition, in keeping with the above results, an im-
provement of carotid intima thickness, an early sign of
atherosclerosis, was also observed following four-months
nCPAP therapy [33].
Strength of our study are, first, that in contrast to
many previous studies performed in otherwise healthy
OSAS, we included patients with concomitant chronic
diseases such as obesity, metabolic syndrome, hyperten-
sion, type 2 diabetes, i.e. a representative sample of the
real-world OSA population. Indeed, prevalence of MS in
our severe OSAS was 70% and 67% had hypertension
and none of these clinical features did change after
nCPAP therapy. By contrast, most published papers refer
to otherwise healthy OSAS, without cardiovascular
comorbidity, poorly representative of the habitual overall
OSA population. Therefore, this is the first study to
demonstrate the efficacy of nCPAP therapy on oxidative
stress and arterial dysfunction in OSA patients with car-
diometabolic risk factors, independent from weight loss
and risk factor management.
Secondly, we assessed oxidative stress by measuring
urinary 8-isoprostanes, which are elevated in severalmetabolic and cardiovascular diseases and possibly
involved in atherosclerosis development and progres-
sion. Thirdly, we measured for the first time sNOX2-dp,
a marker of NOX2 activation, a member of the NADPH
oxidase family which plays an important role in ROS
production and the key mechanisms underlying the
development of endothelial dysfunction and cardiovas-
cular pathophisiology. Indeed, so far, a role of NADPH
oxidase in oxidative and proinflammatory responses
after hypoxia/reoxigenation patterns simulating severe
sleep apnea oxygenation has been demonstrated in a
murine model of sleep apnea [49].
Unattended home PSG should be considered as a
major limitation of this study, although an excellent cor-
relation between the results of attended PSG and home
monitoring has been demonstrated [50]. Indeed, PSG
and home sleep tests use the same respiratory equip-
ment, pulse oximetry equipment, and movement and
position sensors and data generated from each test is
analyzed in the same manner. Home monitoring has also
the ability to record in a natural sleep environment and
patients are tested in the comfort and privacy of their
home. Further limitation of the study is the rather small
number of patients who were included in the nCPAP
study. Finally, the low correlation coefficients between
AHI index and markers of oxidative stress suggest cau-
tion in the interpretation of the results.
Conclusions
In conclusion, the results of our study indicate that
patients with OSAS have an increased oxidative stress
and arterial dysfunction that are partially reversed by
nCPAP treatment.
We believe that our findings, which support a strong
interplay between OSAS, MS, oxidative stress and arter-
ial dysfunction, may be relevant for a better understand-
ing of the pathogenesis of cardiovascular disorders in
patients with OSAS.
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